Collaborating with Patients to Improve IPF Care: Strategies to Enhance Patient QOL and Survival

By clicking the continue button above, I certify I have read the CME information below.

Release Date: February 9, 2018
Expiration Date: February 9, 2019

Recent efforts to improve provider-patient communication and facilitate shared decision-making regarding treatments have been successful, as two-thirds of idiopathic pulmonary fibrosis (IPF) patients report being involved in discussions regarding their care. However, opportunities still exist to ensure alignment of patient and physician priorities and to provide clinicians with the most up-to-date evidence on IPF treatment options. New studies have revealed an increase in patient survival when taking either of the FDA-approved agents to treat IPF, highlighting an important need for early diagnosis and referral to IPF specialty treatment centers.

Collaborating with Patients to Improve IPF Care: Strategies to Enhance Patient QOL and Survival is designed to increase awareness of the latest approaches to assess and manage IPF; thus, prolonging patient survival and improving patient QOL.

This education is intended for pulmonologists, allergists, immunologists, hospitalists, respiratory therapists, rheumatologists, internists, radiologists, pathologists, NPs, PAs, nurses, and other health professionals who are part of the multidisciplinary care team for patients with IPF.

At the conclusion of this activity, participants should be able to demonstrate the ability to:

  • Implement referral and care coordination strategies to make a timely diagnosis of IPF and initiate appropriate treatment in patients with IPF
  • Evaluate evidence regarding the efficacy, safety, and utility of anti-fibrotic and anti-inflammatory therapies for IPF
  • Describe strategies to facilitate a multidisciplinary care team approach, including shared decision-making through provider-patient communication on treatment goals, symptom control, side-effect management

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Potomac Center for Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information about the accreditation of this program, please email:


 Imre Noth, MD
Professor of Medicine
 Section of Pulmonary and Critical Care Medicine
 University of Chicago, Chicago, IL




Imre Noth, MD received his Bachelor of Arts from the University of Pennsylvania. He then went on to complete a Masters of Science in Human Physiology at Georgetown University and received his medical doctorate at the University of Arizona College of Medicine. He completed a residency in internal medicine at the University of California at Davis Medical Center in Sacramento, CA. He then pursued a pulmonary and critical care fellowship at the University of Chicago. Upon completion in 1999, he joined the faculty at the university, where he rose to the rank of Professor of Medicine in 2012.

Dr. Noth is a premiere translational researcher in interstitial lung disease. Over the last decade and a half, he has concentrated his efforts on interstitial lung diseases with a special emphasis on idiopathic pulmonary fibrosis (IPF). This has allowed him to focus on the unique needs of this patient population. Dr. Noth has participated – and continues to participate – as Principal Investigator in numerous clinical trials funded by industry, the National Heart, Lung, and Blood Institute, and the National Institutes of Health (NIH) that focus predominantly on IPF. As the Principal Investigator for a U10 award, he was a member of the NIH-sponsored IPF clinical research network and served on the executive committee for the IPFnet. He has also collaborated on other RO1 and UO1 awards.

His recent research includes studying the relationship between genetics, genomics, and outcomes in IPF, as well as in the conduct of novel clinical trials in IPF. His work in genetics resulted in a RC1 “Challenge” grant award in genetics. He has authored 67 peer-reviewed manuscripts and has mentored numerous trainees. In addition to authoring several book chapters on critical care medicine, Dr. Noth is a reviewer for the American Journal of Respiratory and Critical Care Medicine and the Journal of Respiratory Diseases. He also sits on the editorial board for Chest.

Through the ILD program, he hopes to continue to conduct research that will allow a better understanding of the natural history of interstitial lung diseases and develop better approaches to therapy.

 Mary M. Salvatore, MD, MBA
Associate Professor of Thoracic Radiology
 Mount Sinai Hospital
 New York, NY



Mary M. Salvatore MD, MBA is an Associate Professor of Radiology at Mount Sinai Hospital in New York. She specializes in thoracic radiology with a specific focus in interstitial lung diseases and patterns of fibrosis on CT. She is a passionate teacher and has spoken throughout the country on the early and correct diagnosis of IPF. Dr. Salvatore and colleagues have created and maintain a pulmonary fibrosis registry which has currently enrolled nearly 400 patients. She has initiated a daily journal club in order to provide continuing education for herself and other clinicians and patients on the topic of lung fibrosis by summarizing all recent articles and disseminating by email.

Dr. Salvatore has started a support group at Mount Sinai for patients who have pulmonary fibrosis and their families. She is actively involved in research, retrospectively reviewing well established CTs of UIP and looking at earlier exams to determine earliest CT manifestations of disease. She has written many book chapters and is currently writing a text on CT interpretation for non-radiologists. Her ultimate goal is to affect as many people in a positive way as possible through education and positive attitude.

The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners. The content of this activity was vetted by an external reviewer to assure objectivity and that the activity is free of commercial bias.

The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Imre Noth, MD – Consultant: Boehringer Ingelheim, Genentech, Immuneworks, Sunovion, Global Blood Therapeutics, Veracyte; Research: Afferent, Veracyte; Speaker: Boehringer Ingelheim, Genentech; Speaker’s Bureau: Boehringer Ingelheim, Genentech

Mary M. Salvatore, MD, MBA – Speaker's Bureau: Boehringer Ingelheim, Genentech

Non-faculty Content Contributors
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Chad Willaimson, MS, MBA, CMPP; Blair St. Amand; Lindsay Scott, PT, DPT, ATC:  Nothing to disclose

The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME activity in its entirety, and then complete the posttest and evaluation. The estimated time for completion of this activity is 1.0 hour. To receive their certificates, participants must demonstrate mastery of the presented material via the posttest.  Participant is allowed to take the posttest multiple times.


Jointly provided by the Potomac Center for Medical Education and Rockpointe    


This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.